07:09 AM EST, 11/19/2025 (MT Newswires) -- Aptose Biosciences ( APTOF ) said earlier Wednesday that it is being acquired by Hanmi Pharmaceutical at $2.41 per share.

The price is a 28% premium over Aptose's 30-day VWAP of $1.88 on the Toronto Stock Exchange. Over the past 18 months, Hanmi, who already has a near 20% stake in Aptose, has supported the development of tuspetinib (TUS) through debt facilities to Aptose totaling over US$30 million, a statement said.

Aptose shares will be delisted from the Toronto Stock Exchange when the transaction is completed.

"This transaction not only offers a premium value for our minority shareholders but also enables Aptose to continue the development of TUS combined with standard treatment venetoclax plus azacitidine (VEN+AZA) for acute myeloid leukemia (AML) in the TUSCANY Phase 1/2 clinical study," said Aptose chief executive William Rice.